Tarsus Pharmaceuticals (TARS) Return on Capital Employed (2020 - 2026)

Tarsus Pharmaceuticals' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 11.87% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 1910.0% year-over-year to 11.87%; the TTM figure through Mar 2026 stood at 11.87% (up 1910.0% YoY), while the FY2025 annual figure was 21.26%, up 2885.0% from the prior year.
• Return on Capital Employed was 11.87% for Q1 2026 at Tarsus Pharmaceuticals, up from 17.2% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11.87% in Q1 2026 to a low of 62.25% in Q4 2023.
• Historically, Return on Capital Employed has averaged 35.96% across 5 years, with a median of 30.96% in 2025.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed plunged 3331 bps in 2023, then soared 2789 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 28.93% in 2022, then sank by 115 bps to 62.25% in 2023, then soared by 35 bps to 40.73% in 2024, then surged by 58 bps to 17.2% in 2025, then surged by 31 bps to 11.87% in 2026.
• The last three Return on Capital Employed figures came in at 11.87% (Q1 2026), 17.2% (Q4 2025), and 21.98% (Q3 2025), per Business Quant data.